Cochlear Implants Bone Anchored Hearing Aids Form

Page 1 of 13

Cochlear Implants, Bone Anchored Hearing Aids (BAHA), Auditory Brainstem Implants, and Other Hearing Assistive Devices Medical Guideline

Service: Cochlear Implants, Bone Anchored Hearing Aids (BAHA), Auditory Brainstem Implants, and Other Hearing Assistive Devices

PUM 250-0014

Medical Guideline Committee Approval Q4-2025 Effective Date 03/01/2026

Coverage for Cochlear implants, bone anchored hearing aids (BAHA), auditory brainstem implants, and other hearing assistive devices may vary across plans. Refer to the member’s benefit plan document for coverage details.

Description:

Sensorineural hearing loss occurs with damage to the inner ear/cochlea or in the pathways of the nerves from the inner ear to the brain. Conductive hearing loss occurs due to dampening of sound before it reaches the cochlea and may be caused by blockage or damage along the outer ear, ear canal, or middle ear. Mixed hearing loss is a combination of both conductive and sensorineural hearing loss.

Conventional hearing aids amplify the sound output into the ear canal. These may be “an exclusion of the health plan”.

A cochlear implant is an implantable prosthetic device that processes sounds electronically then transmits electronic stimulation to the cochlea (auditory part of the inner ear) resulting in a sense of sound to individuals with hearing loss. All cochlear implant devices consist of internal and external hardware. External components are worn either behind the ear or on the body. They include a microphone, a sound processor, batteries, and a transmitter that send coded electrical information and power to the internal parts. The internal components are placed surgically underneath the skin and include a receiver and an electrode array within the cochlea.

A bone-anchored hearing aid (BAHA) is a type of hearing aid that provides sound conduction through a titanium implant in one of the bones of the skull. The implant stimulates the cochlea to allow hearing.

Page 2 of 13

Auditory Brainstem Implant (ABI) is a modification of the cochlear implant, in which the electrode array is placed directly into the brain. It is used in individuals who have had surgical removal of auditory nerve tumors and are totally deaf as a result.

Additional devices include semi-implantable hearing aids, and prosthetic hearing assistive devices, hybrid devices that combine cochlear technology with hearing aid technology and hearing aid technology with audio enhancements.

Indications of Coverage:

Note: Many member health plans include specific benefits, exclusions, and requirements for hearing devices. In the event of a conflict, the health plan supersedes this medical guideline.

A. Cochlear implants (unilateral, bilateral sequential or bilateral simultaneous) are considered medically necessary for individuals aged 18 years or older when EITHER of the following criteria (1. OR 2.) are met:

1. Severe post-lingual bilateral sensorineural hearing loss may be considered medically necessary when the individual meets the following criteria:

   o Impairment of greater than 40 dB (decibels) with limited (e.g., best aided word or open-set sentence cognition test at 60% or less, presented at 60 dB) speech perception benefit from hearing aids.

   OR

2. Unilateral sensorineural hearing loss (a traditional cochlear implant FDA approved for the treatment of single side profound sensorineural hearing loss or asymmetrical hearing loss) may be considered medically necessary for when the individual meets ALL of the following criteria:

   o unaided hearing loss of greater than 90 dB in one ear (and normal hearing or mild sensorineural hearing loss in the other ear (i.e., single sided deafness [SSD]); OR
   o profound sensorineural hearing loss in one ear and mild to moderately severe sensorineural hearing loss in the other with less than 30 dB of hearing loss for unilateral, OR 31 to 55 dB hearing loss for asymmetric in contralateral ear, with a difference of at least 15 dB in pure-tone averages between ears (i.e., asymmetric hearing loss [AHL]); AND o Must have trialed appropriately fitted hearing aid in the ear to be implanted and had limited benefit;

Page 3 of 13

OR

o Unilateral sensorineural hearing loss and risk for progression (e.g., due to bacterial meningitis).

AND ALL of the following are met for 1. OR 2. above:

• An evaluation by an audiologist and an otolaryngologist experienced with cochlear implantation indicates the likelihood of success following the implantation of the device.

• MRI confirmation of intact cochlea and cochlear nerve

• Documentation that the current Centers for Disease Control and Prevention (CDC) recommendations for immunization of persons with cochlear implants have been discussed with the patient. (See: Cochlear Implants and Vaccination Recommendations CDC and Preventing Meningitis in Persons with Cochlear Implants | CDC

• No lesions of acoustic nerve or central auditory pathway causing deafness.

• No Organic brain syndrome

NOTE: Bilateral cochlear implantation may be considered medically

necessary when it has been determined that the alternative of unilateral

cochlear implant plus hearing aid in the contralateral ear will not result in

a binaural benefit (i.e., in individuals with hearing loss of a magnitude

where a hearing aid will not produce the required amplification).

B. Cochlear implants with a hybrid cochlear implant device (e.g., Nucleus Hybrid L24 Cochlear Implant System) is considered medically necessary in an individual 18 years of age or older with bilateral severe-to-profound high- frequency sensorineural hearing loss with residual low-frequency hearing sensitivity (that is, able to hear low-frequency sounds) when ALL of the following preimplantation criteria are met:

1. Limited benefit from appropriately fit bilateral hearing aids; AND
2. Normal to moderate hearing loss in the low frequencies (that is, hearing thresholds no poorer than 60 dB hearing level up to and including 500 hertz [averaged over 125, 250, and 500 hertz]) in the ear selected for implantation; AND
3. Severe to profound mid-to high-frequency hearing loss (threshold average of 2000, 3000, and 4000 hertz greater than or equal to 75 dB hearing level) in the ear to be implanted; AND

Page 4 of 13

4. Moderately severe-to-profound mid-to high-frequency hearing loss (threshold average of 2000, 3000, and 4000 hertz greater than or equal to 60 dB hearing level) in the contralateral ear; AND
5. Preoperative speech perception scores as follows: a. Consonant-Nucleus-Consonant word recognition score from 10% to 60% in the ear to be implanted; AND b. Consonant-Nucleus-Consonant word recognition score in the contralateral ear equal to or better than in the ear to be implanted, but not more than 80% in the best-aided condition; AND
6. Individual is free from lesions in the auditory nerve and acoustic areas of the central auditory pathway (nervous system); AND
7. Individual is free from otitis media or other active middle ear infections; AND

8. Individual is able to participate in a post-hybrid cochlear implant rehabilitation program in order to achieve benefit from the hybrid cochlear implant device.

   NOTE: Hybrid cochlear implant devices (e.g., Nucleus Hybrid L24 Cochlear Implant System) are FDA approved, and ONLY for unilateral use.

   C. Cochlear implants (unilateral, bilateral sequential or bilateral simultaneous) are considered medically necessary for individuals from age 5 months to the 18th birthday when EITHER of the following criteria are met:

9. Severe post-lingual bilateral sensorineural hearing loss may be considered medically necessary for when the individual meets ALL of the following criteria: o Age 9 months or older; AND o Hearing loss with unaided pure-tone average thresholds of 70 dB or greater; AND o Three to six-month trial of binaural hearing aids documents lack of minimal improvement (i.e., less than appropriate based on age, developmental stage, or cognitive ability) in auditory development

   OR

10. Unilateral sensorineural hearing loss (a traditional cochlear implant FDA approved for the treatment of single side profound sensorineural hearing loss or asymmetric hearing loss) may be considered medically necessary for when the individual meets ALL of the following criteria:

    o Age 5 years or older; AND

Page 5 of 13

o Hearing loss, unaided, of greater than 90 dB in one ear, and normal hearing or mild sensorineural hearing loss in the other ear (i.e., single sided deafness [SSD]); OR o Profound sensorineural hearing loss in one ear and mild to moderately severe sensorineural hearing loss in the other ear with less than 30 dB hearing loss in contralateral ear, with a difference of at least 15 decibels in pure-tone averages between ears (i.e., asymmetric hearing loss [AHL]); AND o Limited benefit from appropriately fitted hearing aid in ear to be implanted; AND o One month or more experience with contralateral routing of signal (CROS) hearing aid or other relevant non-implantable device (e.g., bone-anchored hearing aid [BAHA]) without benefit

AND ALL of the following are met for 1. OR 2. Above:

• Minimal speech perception (30% or less) or lack of developmentally appropriate auditory milestones measured using parental report scales.

• An evaluation by an audiologist and an otolaryngologist experienced with cochlear implantation indicates there is likelihood of success following the implantation of the device (e.g., NO evidence of central auditory dysfunction or auditory nerve or cochleovestibular anomaly: cochlear aplasia, complete labyrinthine aplasia, lack of cochlear nerve, or vestibular schwannoma excision planned, and cochlear nerve preservation thought possible)

• Documentation that the current CDC recommendations for immunization of persons with cochlear implants have been discussed with the patient or guardian. (See: Cochlear Implants and Vaccination Recommendations CDC and Preventing Meningitis in Persons with Cochlear Implants | CDC

NOTE: Bilateral cochlear implantation may be considered medically necessary when it has been determined that the alternative of unilateral cochlear implant plus hearing aid in the contralateral ear will not result in a binaural benefit (i.e., in individuals with hearing loss of a magnitude where a hearing aid will not produce the required amplification).

C. Auditory Brainstem Implant: Follow MCG ACG-A-0410 (AC) Auditory Brainstem Implants, criteria.

Page 6 of 13

D. Bone-anchored hearing aids (BAHAs) are considered medically necessary for individuals older than five (5) years* for conductive and sensorineural hearing loss unilaterally or bilaterally, when ALL of the following criteria (1 through 5) are met:

1. An air-conduction hearing aid is contraindicated, failed, or not appropriate

2. Pure tone average bone conduction threshold (measured at 0.5, 1, 2, and 3 kHz) less than or equal to 45 dB HL, or level appropriate for model to be implanted (per the documentation provided)

3. Speech discrimination of the indicated ear of 60% or more at elevated sound pressure levels (SPL) during speech discrimination testing using consonant–nucleus–consonant (CNC) words (conventional) testing

4. Cortical bone thickness of at least 3 mm

5. Documentation of at least ONE of the following conditions:

   a. Severe chronic ear infection (for example, external otitis or otitis media)

   b. Malformations of the external or middle ear canal (either congenital or the result of surgery) which are not amenable to surgical reconstruction.

   c. Tumors of the ear canal

   *Note: If a child under age five (5) and meets all other criteria above, including the cortical bone thickness, the “older than five years” criteria may be waived.

   E. Bilateral BAHA is considered medically necessary when all of the criteria in section D. above are met AND there is a symmetrical conductive or mixed hearing loss as defined by a difference between left-side and right-side bone conduction threshold of less than 10 dB on average measured at 0.5, 1, 2, and 3 kHz (4 kHz for OBC and Ponto Pro), or less than 15 dB at individual frequencies.

   F. BAHA may be considered medically necessary as an alternative to an air- conduction hearing aid (including CROS contralateral-routing signal aids), with single-sided sensorineural deafness (≥70 dB) and normal hearing in the other ear.

   The pure tone average air conduction threshold of the normal ear should be better than 20 dB measured at 0.5, 1, 2, and 3 kHz, and pure tone average bone conduction threshold (measured at 0.5, 1, 2, and 3 kHz) should be less than or equal to 45 dB HL.

   G. For Replacement of cochlear implants or other hearing devices, the following documentation must be provided: the reason the device/replacement is needed

Page 7 of 13

(problem or malfunction of the device); and a repair and replacement estimate when applicable. Replacement of components for an existing system are considered medically necessary when the current component is not functional and cannot be repaired or when the current component is no longer adequate for the individual’s daily activities (for example, due to age-appropriate changes in the individual’s capabilities) and improvement is expected with the new component. Replacement or upgrades of functioning components to improve the individual’s appearance or due to psychosocial concerns is considered not medically necessary and may also be a health plan exclusion. Components are generally expected to be useable for a period of three years. The member’s health plan must be referenced to determine the DME benefits for repair or replacement of external components.

Limitations of Coverage:

Benefit Limitations: Please note that in listing services or examples, when we say “this includes,” it is not our intent to limit the description to that specific list. When we do intend to limit a list of services or examples, we state specifically that the list “is limited to.”

A. Review health plan and endorsements for exclusions and prior authorization or benefit requirements.

B. If requested/used for a condition or diagnosis other than is listed in the Indications of Coverage, it will be considered experimental, investigational, and unproven to affect health outcomes.

C. If requested/used for a condition or diagnosis that is listed in the Indications of Coverage; but the criteria are not met, it will be considered not medically necessary.

D. Cochlear implants are considered not medically necessary for treatment of tinnitus or any other medical diagnosis other than sensorineural hearing loss.

E. Cochlear implants are considered not medically necessary when any of the following (1 through 6) are documented:

1. Cochlear aplasia (failure of cochlear development)

2. Acute middle ear infection

3. Dysfunctional acoustic nerve

4. Cancer of the head or neck

5. Replacement or upgrades of components are ordered to improve the

   individual’s appearance or due to psychosocial concerns

Page 8 of 13

6. Underlying organic brain syndrome

   F. Implantable and semi-implantable hearing aids and transducer systems are considered experimental, investigational, and unproven to affect health outcomes.

   G. Semi-implantable Electromagnetic Hearing Aides and Transducer systems are considered experimental, investigational, and unproven to affect health outcomes.

   H. Maxim System is considered experimental, investigational, and unproven to affect health outcomes.

   I. Lyric and Lyric2 Hearing Aid systems are considered experimental, investigational, and unproven to affect health outcomes.

   J. Vibrant Soundbridge System, the Soundtec Direct Drive system, or the semi- implantable Middle Ear Transducer (MET) Ossicular Stimulator System are considered experimental, investigational, and unproven to affect health outcomes.

   K. Esteem Hearing Implant (implantable middle ear hearing aid) is considered experimental, investigational, and unproven to affect health outcomes.

   L. Ponto Plus and Ponto Plus Power bone anchored hearing aid for unilateral conductive hearing loss are considered experimental, investigational, and unproven to affect health outcomes.

   M. Bilateral (binaural) cochlear implants, in individuals over age 18, who are pre- lingually deafened, have moderate deafness or other disabilities or structural abnormalities that could interfere with the procedure, are considered investigative, as there is insufficient peer-reviewed scientific literature in these populations.

   N. BAHAs are considered investigational and unproven for individuals with bilateral pure sensorineural hearing loss.

   O. Intraoral Bone Conduction Hearing Aids (e.g., SoundBite) are considered experimental, investigational, and unproven to affect health outcomes.

   P. Laser or Light Based (Light Driven) Hearing Aids (EarLens Contact Hearing Device) are considered experimental, investigational, and unproven to affect health outcomes.

   Q. Vestibular implantation for Meniere’s disease or vertigo is considered experimental, investigational, and unproven as it is not cleared by the U.S. FDA for use.

Page 9 of 13

Documentation Required:

• Standard Written Order (SWO), prescribed by a qualified healthcare provider concerning the member’s diagnosis.
• Medical record information (including continued need/use if applicable) and medical necessity. Office notes, Test results, including audiogram (pure tone and bone conduction) report. • Correct coding for the item/service that meets all the coding guidelines.

Disclaimer: This guideline is for informational purposes only and does not constitute medical advice, plan authorization, an explanation of benefits, or a guarantee of payment. Benefit plans vary in coverage and some plans may not provide coverage for all services listed in this guideline. Coverage decisions are subject to all terms and conditions of the applicable benefit plan, including specific exclusions and limitations, and to applicable state and federal law. Some benefit plans administered by the organization may not utilize Medical Affairs medical guideline in all their coverage determinations. Contact customer services as listed on the member card for specific plan, benefit, and network status information.

Medical guidelines are based on constantly changing medical science and are reviewed annually and subject to change. The organization uses tools developed by third parties, such as the evidence-based clinical guidelines developed by MCG to assist in administering health benefits. This medical guideline and MCG guidelines are intended to be used in conjunction with the independent professional medical judgment of a qualified health care provider. To obtain additional information about MCG, email medical.policies@wpsic.com. Coverage of all services is subject to medical necessity and services deemed experimental, investigational, and/or unproven are therefore not considered medically necessary under the terms of the clinical guidelines and will not be covered.

Cochlear Implants, Bone Anchored Hearing Aids (BAHA), Auditory Brainstem Implants, and Other Hearing Assistive Devices are considered medically necessary only when indicated per the most current medical references and specialty society guidelines, such as MCG, NCCN, etc.

State mandates, laws or benchmark supersede this medical guideline.

Guideline Review History:

Implemented 10/01/15, 10/01/16, 10/01/17, 10/01/18, 07/01/19, 12/01/20, 12/01/21, 12/01/22, 08/01/23, 07/01/24, 03/01/26 Medical Guideline Committee Approval 06/13/14, 06/12/15, 06/03/16, 06/16/17, 06/15/18, 03/15/19, 08/20/20, 07/29/21, 07/28/22, 07/27/23, 06/27/24, Q4 2025 Reviewed

06/13/14, 06/12/15, 06/03/16, 06/16/17, 06/15/18, 03/15/19, 08/20/20, 07/29/21, 07/28/22, 07/27/23, 06/27/24, Q4 2025 Revised 06/12/15, 06/03/16, 06/16/17, 06/15/18, 03/15/19, 08/20/20

 Note: For review/revision history prior to 2014 see previous Medical Guideline

Approved by the Medical Director

Page 10 of 13

Codes: The following codes for treatments and procedures applicable to this document are included below for informational purposes.

Code Description 0725T VESTIBULAR DEVICE IMPLANTATION, UNILATERAL 0726T REMOVAL OF IMPLANTED VESTIBULAR DEVICE, UNILATERAL 0727T REMOVAL AND REPLACEMENT OF IMPLANTED VESTIBULAR DEVICE, UNILATERAL 0728T DIAGNOSTIC ANALYSIS OF VESTIBULAR IMPLANT, UNILATERAL; WITH INITIAL PROGRAMMING 0729T DIAGNOSTIC ANALYSIS OF VESTIBULAR IMPLANT, UNILATERAL; WITH SUBSEQUENT PROGRAMMING 69710 IMPLANTATION OR REPLACEMENT OF ELECTROMAGNETIC BONE CONDUCTION HEARING DEVICE IN TEMPORAL BONE 69711 REMOVAL OR REPAIR OF ELECTROMAGNETIC BONE CONDUCTION HEARING DEVICE IN TEMPORAL BONE 69714 IMPLANTATION, OSSEOINTEGRATED IMPLANT, SKULL; WITH PERCUTANEOUS ATTACHMENT TO EXTERNAL SPEECH PROCESSOR 69716 IMPLANTATION, OSSEOINTEGRATED IMPLANT, SKULL; WITH MAGNETIC TRANSCUTANEOUS ATTACHMENT TO EXTERNAL SPEECH PROCESSOR, WITHIN THE MASTOID AND/OR RESULTING IN REMOVAL OF LESS THAN 100 SQ MM SURFACE AREA OF BONE DEEP TO THE OUTER CRANIAL CORTEX 69717 REPLACEMENT (INCLUDING REMOVAL OF EXISTING DEVICE), OSSEOINTEGRATED IMPLANT, SKULL; WITH PERCUTANEOUS ATTACHMENT TO EXTERNAL SPEECH PROCESSOR 69719 REPLACEMENT (INCLUDING REMOVAL OF EXISTING DEVICE), OSSEOINTEGRATED IMPLANT, SKULL; WITH MAGNETIC TRANSCUTANEOUS ATTACHMENT TO EXTERNAL SPEECH PROCESSOR, WITHIN THE MASTOID AND/OR INVOLVING A BONY DEFECT LESS THAN 100 SQ MM SURFACE AREA OF BONE DEEP TO THE OUTER CRANIAL CORTEX 69726 REMOVAL, ENTIRE OSSEOINTEGRATED IMPLANT, SKULL; WITH PERCUTANEOUS ATTACHMENT TO EXTERNAL SPEECH PROCESSOR

Page 11 of 13

69727 REMOVAL, ENTIRE OSSEOINTEGRATED IMPLANT, SKULL; WITH MAGNETIC TRANSCUTANEOUS ATTACHMENT TO EXTERNAL SPEECH PROCESSOR, WITHIN THE MASTOID AND/OR INVOLVING A BONY DEFECT LESS THAN 100 SQ MM SURFACE AREA OF BONE DEEP TO THE OUTER CRANIAL CORTEX 69728 REMOVAL, ENTIRE OSSEOINTEGRATED IMPLANT, SKULL; WITH MAGENETIC TRANSCUTANEOUS ATTACHMENT TO EXTERNAL SPEECH PROCESSOR OUTSIDE THE MASTOID AND INVOLVING A BONY DEFECT GREATER THAN OR EQUAL TO 100 SQ MM SURFACE AREA OF BONE DEEP TO THE OUTER CRANIAL CORTEX 69729 IMPLANTATION, OSSEOINTEGRATED IMPLANT, SKULL; WITH MAGNETIC TRANSCUTANEOUS ATTACHMENT TO EXTERNAL SPEECH PROCESSOR, OUTSIDE OF THE MASTOID AND RESULTING IN REMOVAL OF GREATER THAN OR EQUAL TO 100 SQ MM SURFACE AREA OF BONE DEEP TO THE OUTER CRANIAL CORTEX 69730 REPLACEMENT (INCLUDING REMOVAL OF EXISTING DEVICE), OSSEOINTEGRATED IMPLANT, SKULL; WITH MAGNETIC TRANSCUTANEOUS ATTACHMENT TO EXTERNAL SPEECH PROCESSOR, OUTSIDE THE MASTOID AND INVOLVING A BONY DEFECT GREATER THAN OR EQUAL TO 100 SQ MM SURFACE AREA OF BONE DEEP TO THE OUTER CRANIAL CORTEX 69930 COCHLEAR DEVICE IMPLANTATION, WITH OR WITHOUT MASTOIDECTOMY L8613 OSSICULA IMPLANT L8614 COCHLEAR DEVICE, INCLUDES ALL INTERNAL AND EXTERNAL COMPONENTS L8619 COCHLEAR IMPLANT, EXTERNAL SPEECH PROCESSOR AND CONTROLLER, INTEGRATED SYSTEM, REPLACEMENT L8690 AUDITORY OSSEOINTEGRATED DEVICE, INCLUDES ALL INTERNAL AND EXTERNAL COMPONENTS L8691 AUDITORY OSSEOINTEGRATED DEVICE, EXTERNAL SOUND PROCESSOR, EXCLUDES TRANSDUCER/ACTUATOR, REPLACEMENT ONLY, EACH

Associated Procedure Codes 92601 DIAGNOSTIC ANALYSIS OF COCHLEAR IMPLANT, PATIENT YOUNGER THAN 7 YEARS OF AGE; WITH PROGRAMMING 92602 DIAGNOSTIC ANALYSIS OF COCHLEAR IMPLANT, PATIENT YOUNGER THAN 7 YEARS OF AGE; SUBSEQUENT REPROGRAMMING 92603 DIAGNOSTIC ANALYSIS OF COCHLEAR IMPLANT, AGE 7 YEARS OR OLDER; WITH PROGRAMMING

Page 12 of 13

92604 DIAGNOSTIC ANALYSIS OF COCHLEAR IMPLANT, AGE 7 YEARS OR OLDER; SUBSEQUENT REPROGRAMMING 92622 DIAGNOSTIC ANALYSIS, PROGRAMMING, AND VERIFICATION OF AN AUDITORY OSSEOINTEGRATED SOUND PROCESSOR, ANY TYPE; FIRST 60 MINUTES
92623 DIAGNOSTIC ANAYLSIS PROGRAMMING, AND VERIFICATION OF AN AUDITORY OSSEOINTEGRATED SOUND PROCESSOR ANY TYPE; EACH ADDITIONAL 15 MINUTES (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE)
L8615 HEADSET/HEADPIECE FOR USE WITH COCHLEAR IMPLANT DEVICE, REPLACEMENT L8616 MICROPHONE FOR USE WITH COCHLEAR IMPLANT DEVICE, REPLACEMENT L8617 TRANSMITTING COIL FOR USE WITH COCHLEAR IMPLANT DEVICE, REPLACEMENT L8618 TRANSMITTER CABLE FOR USE WITH COCHLEAR IMPLANT DEVICE OR AUDITORY OSSEOINTEGRATED DEVICE, REPLACEMENT L8621 ZINC AIR BATTERY FOR USE WITH COCHLEAR IMPLANT DEVICE AND AUDITORY OSSEOINTEGRATED SOUND PROCESSORS, REPLACEMENT, EACH L8622 ALKALINE BATTERY FOR USE WITH COCHLEAR IMPLANT DEVICE, ANY SIZE, REPLACEMENT, EACH L8623 LITHIUM ION BATTERY FOR USE WITH COCHLEAR IMPLANT DEVICE SPEECH PROCESSOR, OTHER THAN EAR LEVEL, REPLACEMENT, EACH L8624 LITHIUM ION BATTERY FOR USE WITH COCHLEAR IMPLANT OR AUDITORY OSSEOINTEGRATED DEVICE SPEECH PROCESSOR, EAR LEVEL, REPLACEMENT, EACH L8625 EXTERNAL RECHARGING SYSTEM FOR BATTERY FOR USE WITH COCHLEAR IMPLANT OR AUDITORY OSSEOINTEGRATED DEVICE, REPLACEMENT ONLY, EACH L8627 COCHLEAR IMPLANT, EXTERNAL SPEECH PROCESSOR, COMPONENT, REPLACEMENT L8628 COCHLEAR IMPLANT, EXTERNAL CONTROLLER COMPONENT, REPLACEMENT L8629 TRANSMITTING COIL AND CABLE, INTEGRATED, FOR USE WITH COCHLEAR IMPLANT DEVICE, REPLACEMENT L8692 AUDITORY OSSEOINTEGRATED DEVICE, EXTERNAL SOUND PROCESSOR, USED WITHOUT OSSEOINTEGRATION, BODY WORN, INCLUDES HEADBAND OR OTHER MEANS OF EXTERNAL ATTACHMENT

Page 13 of 13

L8693 AUDITORY OSSEOINTEGRATED DEVICE ABUTMENT, ANY LENGTH, REPLACEMENT ONLY L8694 AUDITORY OSSEOINTEGRATED DEVICE, TRANSDUCER/ACTUATOR, REPLACEMENT ONLY, EACH L9900 ORTHOTIC AND PROSTHETIC SUPPLY, ACCESSORY, AND/OR SERVICE COMPONENT OF ANOTHER HCPCS "L" CODE S2330 IMPLANTATION OF MAGNETIC COMPONENT OF SEMI- IMPLANTABLE HEARING DEVICE ON OSSICLES IN MIDDLE EAR V5095 SEMI-IMPLANTABLE MIDDLE EAR HEARING PROSTHESIS V5273 ASSISTIVE LISTENING DEVICE, FOR USE WITH COCHLEAR IMPLANT